Cargando…
Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management
Precision medicine in the clinical management of cancer may be achieved through the diagnostic platform called “liquid biopsy”. This method utilizes the detection of biomarkers in blood for prognostic and predictive purposes. One of the latest blood born markers under investigation in the field of l...
Autores principales: | Elazezy, Maha, Joosse, Simon A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197739/ https://www.ncbi.nlm.nih.gov/pubmed/30364656 http://dx.doi.org/10.1016/j.csbj.2018.10.002 |
Ejemplares similares
-
BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
por: Elazezy, Maha, et al.
Publicado: (2021) -
Detection and Characterization of Estrogen Receptor α Expression of Circulating Tumor Cells as a Prognostic Marker
por: Ningsi, Retno, et al.
Publicado: (2022) -
Circulating tumor cells and DNA as liquid biopsies
por: Heitzer, Ellen, et al.
Publicado: (2013) -
Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma
por: Lyu, Xueying, et al.
Publicado: (2022) -
Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
por: Ye, Qianwei, et al.
Publicado: (2019)